Egfr activity is associated with worse cancer prognosis, and inhibition of Egfr signaling has been proposed as a therapeutic approach in advanced prostate cancer (Kim et al., 2006; Guérin et al., 2010; Xiong et al., 2020). This evidence concerns the gene EGFR and Familial prostate cancer.